Medical Cannabis

Avicanna released information on a new study through MyMedi.ca which will look into the use of medical cannabis for various health ailments such as pain, anxiety, epilepsy, sleep, and depression.

A ruling is expected this week regarding the lawsuit challenging the validity of signatures collected for two medical cannabis measures.

Panelists discussed the impacts of cannabis as a schedule 3 substance on research, legislation, patients, and more.

As discussions about the federal scheduling of cannabis continue, efforts by medical cannabis advocates are intensifying. One such advocate is Americans for Safe Access (ASA), a nonprofit organization founded by patients for patients. Since 2002, ASA has been championing the rights of medical cannabis patients and has recently launched new campaigns and strategies to refocus attention on patient needs. In this interview, Steph Sherer, founder and president of ASA, reflects on past successes in medical cannabis advocacy, shares her perspective on recent cannabis and hemp policymaking, and outlines the next steps for advancing a unified medical cannabis message on Capitol Hill—a message that could bring about the changes patients have long awaited.

A recently published study found that patients using medical marijuana reported a significant increase in subjective improvements of gastrointestinal (GI) symptom severity, compared to not using medical marijuana.

This month’s Healer webinar provided a deep dive into several studies on cannabis for various conditions.

The majority of comments on the scheduling of cannabis favored change, though several other aspects of cannabis policy remain to be addressed.

Tilray’s Aphria RX obtained a cannabis trading license recently in Germany.

California’s bill creating new restrictions on intoxicating hemp products has prompted responses citing negative impacts on patients and businesses.

Americans for Safe Access, a medical cannabis patient advocacy organization, held a briefing on the final day of the comment period for the proposed rulemaking on cannabis.

This month’s webinar discussed studies conducted on cannabis and psychedelics for various conditions including anxiety and autism spectrum disorder.

The Senate’s latest attempt at legal medical cannabis access for patients was added to a bill on hemp regulations.

Let’s take a look at the most recent webinars on cannabis research and medicine to catch up on industry trends and innovations.

This month’s Healer webinar discussed several studies on cannabis and symptoms of dementia and cognitive decline.

Nebraska advocates are a few weeks away from knowing if two medical cannabis measures have enough signatures to qualify to appear on the 2024 ballot.

The new law eliminates the 37% excise tax for medical cannabis cardholders for certain products.

This webinar from MM411 explored the far-ranging studies of Dr. Raphael Mechoulam and Dr. Ethan Russo on the science and medicine of cannabis and other plants.

The final installment of this webinar series discussed recommendations for new policies integrating cannabis into harm reduction efforts.

Focusing on the potential effects for medical cannabis patients, Americans for Safe Access held a high-level presentation and discussion on the rescheduling of cannabis.

As the keynote speaker for Cannabis Science Conference Spring 2024, Jamila Owens-Todd discussed the various ways to approach plant medicine and manufacturing.

Kentucky Governor signs HB 829, and introduces lottery for dispensary applications.

As we celebrate the 4/20 holiday, here is a selection of medical cannabis coverage we have explored in the cannabis industry this year so far.

Keynote speaker Jamila Owens-Todd shares her perspectives on cannabis from medical and science viewpoints.

One step forward, two steps back: updates on cannabis legal movements in three different states.

After stalled attempts over the years, a bill that would create a medical cannabis program in the Sunflower State has made an appearance.